FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978095514> ?p ?o ?g. }

• W2978095514 endingPage "S467" @default.
• W2978095514 startingPage "S467" @default.
• W2978095514 abstract "Purpose: Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor-alpha, is an established treatment for Crohn's disease. Several recent studies of infliximab in patients with ulcerative colitis (UC) have yielded conflicting results. We conducted a systematic review to assess the efficacy of infliximab in ulcerative colitis. Methods: MEDLINE (from 1966–2006) and abstracts of gastroenterology scientific meetings in the last 5 years were searched (search date June 2006). Open label and randomized control trials in adult subjects were included. Standard forms were used to extract data regarding study design, duration of study, outcome measures, and adverse effects by two independent reviewers. Results: 9 studies satisfied our inclusion criteria: 5 randomized control trials(RCTs) [829 pts] and 4 open label trials [47 pts]. Significant heterogeneity was present among the studies. 3 RCTs evaluated pts with moderate to severe UC, while 1 RCT evaluated pts with acute UC. 1 RCT evaluated the role of infliximab as a rescue therapy in severe UC. 4 RCTs involved pts with steroid refractory UC. In the open label trials, 3 dealt with severe UC while 1 dealt with moderate to severe UC. All of the pts in the open label trials had steroid refractory disease. The dose of infliximab was 5mg/kg in all the studies (RCTs and open label trials), but 2 RCTs also used 10mg/kg of infliximab. 4 RCTs administered 2 or more infusions of infliximab, while all the open label trials administered a single infusion of infliximab. A validated scoring system was used to assess disease activity in all the studies. The primary end point in the trials was evaluated at different time points in all the studies. 2 RCTs found 5mg/kg of infliximab was superior to placebo [OR 5.06; 95% CI 3.09–8.30] in patients with moderate to severe UC at 30 weeks. Similar benefit was noted with a higher dose of 10mg/kg (3.78; 95% CI 2.40–5.96). 3 open label trials also found infliximab induced a clinical response, while 1 open label trial did not. 1 RCT showed that infliximab decreased the rate of colectomy in severe UC patients (OR 4.9; 95% CI 1.4–17). Infliximab was well tolerated in all the studies. Conclusions: Infliximab induces clinical remission in patients with active UC. The optimal dose is 5mg/kg. Additionally, infliximab may also be useful as a rescue therapy in severe UC. However, more studies are needed to verify findings from these smaller studies." @default.
• W2978095514 created "2019-10-10" @default.
• W2978095514 creator A5021106928 @default.
• W2978095514 creator A5044246081 @default.
• W2978095514 creator A5054400793 @default.
• W2978095514 creator A5066483552 @default.
• W2978095514 date "2006-09-01" @default.
• W2978095514 modified "2023-10-16" @default.
• W2978095514 title "Role of Infliximab in Ulcerative Colitis" @default.
• W2978095514 doi "https://doi.org/10.14309/00000434-200609001-01200" @default.
• W2978095514 hasPublicationYear "2006" @default.
• W2978095514 type Work @default.
• W2978095514 sameAs 2978095514 @default.
• W2978095514 citedByCount "0" @default.
• W2978095514 crossrefType "journal-article" @default.
• W2978095514 hasAuthorship W2978095514A5021106928 @default.
• W2978095514 hasAuthorship W2978095514A5044246081 @default.
• W2978095514 hasAuthorship W2978095514A5054400793 @default.
• W2978095514 hasAuthorship W2978095514A5066483552 @default.
• W2978095514 hasConcept C126322002 @default.
• W2978095514 hasConcept C141071460 @default.
• W2978095514 hasConcept C168563851 @default.
• W2978095514 hasConcept C197934379 @default.
• W2978095514 hasConcept C2777138892 @default.
• W2978095514 hasConcept C2778260677 @default.
• W2978095514 hasConcept C2779134260 @default.
• W2978095514 hasConcept C2780479503 @default.
• W2978095514 hasConcept C535046627 @default.
• W2978095514 hasConcept C71924100 @default.
• W2978095514 hasConcept C90924648 @default.
• W2978095514 hasConceptScore W2978095514C126322002 @default.
• W2978095514 hasConceptScore W2978095514C141071460 @default.
• W2978095514 hasConceptScore W2978095514C168563851 @default.
• W2978095514 hasConceptScore W2978095514C197934379 @default.
• W2978095514 hasConceptScore W2978095514C2777138892 @default.
• W2978095514 hasConceptScore W2978095514C2778260677 @default.
• W2978095514 hasConceptScore W2978095514C2779134260 @default.
• W2978095514 hasConceptScore W2978095514C2780479503 @default.
• W2978095514 hasConceptScore W2978095514C535046627 @default.
• W2978095514 hasConceptScore W2978095514C71924100 @default.
• W2978095514 hasConceptScore W2978095514C90924648 @default.
• W2978095514 hasLocation W29780955141 @default.
• W2978095514 hasOpenAccess W2978095514 @default.
• W2978095514 hasPrimaryLocation W29780955141 @default.
• W2978095514 hasRelatedWork W1968760412 @default.
• W2978095514 hasRelatedWork W2014462309 @default.
• W2978095514 hasRelatedWork W2064877889 @default.
• W2978095514 hasRelatedWork W2122325622 @default.
• W2978095514 hasRelatedWork W2296926020 @default.
• W2978095514 hasRelatedWork W2576474053 @default.
• W2978095514 hasRelatedWork W2899408960 @default.
• W2978095514 hasRelatedWork W2952464799 @default.
• W2978095514 hasRelatedWork W46359855 @default.
• W2978095514 hasRelatedWork W2978685749 @default.
• W2978095514 hasVolume "101" @default.
• W2978095514 isParatext "false" @default.
• W2978095514 isRetracted "false" @default.
• W2978095514 magId "2978095514" @default.
• W2978095514 workType "article" @default.